FarmaSino Pharmaceuticals (Anhui) Co., Ltd is located in the Economic Development Zone, Suzhou, Anhui, covering an area of 50 acres, and serves as one of FarmaSino's production bases. The total investment in the project is 1 billion RMB. The first phase of the project focuses on the production of various pharmaceutical products, including 600 tons of Phosphomycin Phosphate, 250 tons of Calcium Phosphomycin, 50 tons of Sodium Phosphomycin, 50 tons of Amphotericin B for Injection, and 1000 kg of Sucrose Octasulfate. After the first phase of the project is completed, it is expected to generate an annual output value of 500 million RMB. The second phase of the project is currently under construction.

Located in the Nanjing Economic Development Zone of Jiangsu Province, this facility covers an area of 20,000 square meters. It encompasses a chemical drug R&D center and formulation production workshops (including various dosage forms such as oral solid formulations, oral solutions, inhalation formulations, injectables, topicals, and anti-tumor formulations). The projected annual production capacity includes 1.5 billion tablets, 1 billion capsules, 30 million bags of powders, 60 million bottles of multi-dose oral liquids, and 1.2 billion bottles of single-dose oral liquids.

Located in "China Medical City" in Taizhou, Jiangsu, is one of FarmaSino's formulation production bases. Its main business includes export-oriented MAH and other entrusted productions. The production workshops comply with GMP standards and specialize in manufacturing tablets and hard capsule formulations. Zonta Pharma has obtained production approvals for 2 products, Cefalexin Capsules and Chloramphenicol Capsules. It holds a Drug Manufacturing License for capsule formulations, tablet formulations, oral liquid formulations, and granule formulations. With a total of 6 pharmaceutical production lines, including an annual capacity of 1 billion tablets/capsules and 30 million bottles of oral liquid formulations, Zonta Pharma can efficiently fulfill large-scale drug processing and production requirements for both domestic and international clients.

Located in Jiangsu Life Science Park, Qixia High tech Zone, Nanjing City, JiangsuProvince. Health Port Biotech Co., Ltd., a wholly-owned subsidiary of FarmaSino Medicals, specialized in R&D,manufacturing and sales of IVD( In Vitro Diagnostics ). Health Port has established a 700-square-meter GMP workshop. As the research and production arm of FarmaSino Medicals, it plays a crucial role in supporting the global development of the brands FarmaPet and FarmaMed.